Stage 1 prostate adenocarcinoma is localized, non-aggressive, and often detected through routine screenings like PSA tests and DREs. Diagnosis involves PSA levels, Gleason scores, and possibly ...

Serum biomarkers in metastatic castration-resistant prostate cancer (mCRPC) patients receiving [177Lu]Lu-PSMA-617 therapy: Post hoc analysis of a phase II clinical trial. Individual patient data (IPD) ...

Scientists at the Herbert Irving Comprehensive Cancer Center (HICCC) have discovered a key mechanism that makes prostate cancer cells resistant to the latest drugs used to treat them. Their findings, ...

Chimeric RNA landscape in the Chinese population and the role of SFT2D2-TBX19 in prostate cancer progression. Risk stratification using the Decipher 22-gene genomic classifier (GC) and digital ...

PEACE-2 finds adding cabazitaxel to ADT plus radiotherapy fails to improve survival in high-risk localized prostate cancer, while increasing severe toxicities and deaths.

Genitourinary medical oncologist Dr. Michael Morris is part of a new MSK program focused on better treatments for neuroendocrine cancers, which sometimes develop when prostate and lung cancers become ...

Overall these findings indicate that adding cabazitaxel to long-term androgen deprivation therapy and radiotherapy did not improve long-term outcomes and increased toxicity in men with high-risk ...